PCLX-001 Uses, Dosage, Side Effects and more

PCLX-001 is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by Pacylex Pharmaceuticals. Current studies have shown that PCLX-001 works differently than other known cancer drugs and has high activity and positive results in breast, lung, bladder and pancreas cancers.

Attribute	Details
Trade Name	PCLX-001
Generic	PCLX-001
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	January 7, 2025 at 1:49 am

Innovators Monograph